Perspectiva histórica, mecanismos patológicos, variantes clínicas y tratamiento | 20 MAY 18

Síndrome de Guillain Barré

Es una polirradiculoneuropatía inflamatoria aguda inducida por inmunidad, que se manifiesta con hormigueo, debilidad progresiva y dolor
Autor/a: Eelco F.M. Wijdicks EFM, Klein CJ Mayo Clin Proc. 2017; 92(3):467-479
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas

Referencias bibliográficas:

1. Guillain G, Barré JA, Strohl A. Sur un syndrome de radiculonévrite avec hyperalbuminose du liquide céphalo-rachidien sans réaction cellulaire: remarques sur les caractères cliniques et graphiques des reflexes tendineux. Bull Memoires Soc Med Hopitaux Paris. 1916;40:1462-1470.

2. Willison HJ, Goodfellow JA. GBS100: Celebrating a century of progress in Guillain-Barré syndrome. La Jolla, CA: Peripheral Nerve Society; 2016.

3. Saiz JC, Vázquez-Calvo Á, Blázquez AB, Merino-Ramos T, Escribano-Romero E, Martín-Acebes MA. Zika virus: the latest newcomer. Front Microbiol. 2016;7:496.

4. Mahecha MP, Ojeda E, Vega DA, Sarmiento-Monroy JC, Anaya JM. Guillain-Barré syndrome in Colombia: where do we stand now [published online ahead of print July 15, 2016]? Immunol Res. http://dx.doi.org/10.1007/s12026-016-8816-8.

5. Broutet N, Krauer F, Riesen M, et al. Zika virus as a cause of neurologic disorders. N Engl J Med. 2016;374(16):1506-1509.

6. Rogoff JB. Pronunciation of Dr Georges Guillain’s name. JAMA. 1977;237(23):2470.

7. Landry O. Note sur la paralysie ascendante aigu_e. Gaz Hebd Med. 1859;6:472-474.

8. Wijdicks EFM, Ropper AH. The Guillain-Barre syndrome. In: Koehler PJ, Bruyn GW, Pearce JMS, eds. Neurological Eponyms. New York, NY: Oxford University Press; 2000:219-226.

9. Haymaker WE, Kernohan JW. The Landry-Guillain-Barré syndrome: a clinicopathologic report of 50 fatal cases and a critique of the literature. Medicine (Baltimore). 1949;28(1):59-141.

10. Wiederholt WC, Mulder DW, Lambert EH. The Landry-Guillain-Barre-Strohl syndrome or polyradiculoneuropathy: historical review, report on 97 patients, and present concepts. Mayo Clin Proc. 1964;39:427-451.

11. Kurland LT, Wiederholt WC, Kirkpatrick JW, Potter HG, Armstrong P. Swine influenza vaccine and Guillain-Barré syndrome: epidemic or artifact? Arch Neurol. 1985;42(11): 1089-1090.

12. Feasby TE, Gilbert JJ, Brown WF, et al. An acute axonal form of Guillain-Barré polyneuropathy. Brain. 1986;109(pt 6):1115-1126.

13. McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol. 1993;33(4):333-342.

14. Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China: relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995;118(pt 3):597-605.

15. Griffin JW, Li CY, Ho TW, et al. Guillain-Barré syndrome in northern China: the spectrum of neuropathological changes in clinically defined cases. Brain. 1995;118(pt 3):577-595.

16. Griffin JW, Li CY, Ho TW, et al. Pathology of the motorsensory axonal Guillain-Barré syndrome. Ann Neurol. 1996;39(1):17-28.

17. Yuki N, Yoshino H, Sato S, Miyatake T. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology. 1990;40(12):1900-1902.

18. Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology. 1985;35(8):1096-1104.

19. van der Meché FG, Schmitz PI; Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome.

N Engl J Med. 1992;326(17):1123-1129.

20. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet. 1997;349(9047):225-230.

21. Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter: immunotherapy for Guillain-Barre syndrome; report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003;61(6):736-740.

22. Ropper AH, Wijdicks EFM, Truax BT. Guillain-Barré Syndrome. Philadelphia, PA: FA Davis; 1991.

23. Jacobs BC, Rothbarth PH, van der Meché FG, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology. 1998;51(4):1110-1115.

24. McCarthy N, Andersson Y, Jormanainen V, Gustavsson O, Giesecke J. The risk of Guillain-Barré syndrome following infection with. Campylobacter jejuni Epidemiol Infect. 1999;122(1):15-17.

25. Mori M, Kuwabara S, Miyake M, et al. Haemophilus influenza infection and Guillain-Barré syndrome. Brain. 2000;123(pt 10):2171-2178.

26. Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med. 1995;333(21):1374-1379.

27. Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med. 1998;339(25):1797-1802.

28. Poland GA, Jacobsen SJ. Influenza vaccine, Guillain-Barré syndrome, and chasing zero. Vaccine. 2012;30(40):5801-5803.

29. Salmon DA, Proschan M, Forshee R, et al; H1N1 GBS Meta-Analysis Working Group. Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet. 2013;381(9876):1461-1468.

30. Nagarajan E, Rubin M, Wijdicks EFM, et al. Guillain-Barré syndrome after surgical procedures: predisposing factors and outcome. Neurol Clin Pract in revision.

31. Yuki N. Molecular mimicry and Guillain-Barré syndrome [in Japanese]. Brain Nerve. 2015;67(11):1341-1346.

32. Islam Z, Jacobs BC, van Belkum A, et al. Axonal variant of Guillain-Barré syndrome associated with Campylobacter infection in Bangladesh. Neurology. 2010;74(7):581-587.

33. Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol. 2000;48(4):624-631.

34. Yuki N, Susuki K, Koga M, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc Natl Acad Sci U S A. 2004;101(31):11404-11409.

35. Yuki N, Taki T, Inagaki F, et al. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med. 1993;178(5):1771-1775.

36. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol. 1992;31(6):677-679.

37. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med. 1956;255(2):57-65.

38. Phillips MS, Stewart S, Anderson JR. Neuropathological findings in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry. 1984;47(5):492-495.

39. Ropper AH. Miller Fisher syndrome and other acute variants of Guillain-Barré syndrome. Baillieres Clin Neurol. 1994;3(1):95-106.

40. Yuan CL, Wang YJ, Tsai CP. Miller Fisher syndrome: a hospital based retrospective study. Eur Neurol. 2000;44(2):79-85.

41. Ropper AH. Unusual clinical variants and signs in Guillain-Barré syndrome. Arch Neurol. 1986;43(11):1150-1152.

42. van den Berg B, Fokke C, Drenthen J, van Doorn PA, Jacobs BC. Paraparetic Guillain-Barré syndrome. Neurology. 2014;82(22):1984-1989.

43. Bolton CF, Chen R, Wijdicks EFM, Zifco UA. Neurology of Breathing. Amsterdam, the Netherlands: Elsevier; 2004.

44. Derenne JP, Macklem PT, Roussos C. The respiratory muscles: mechanics, control, and pathophysiology. Am Rev Respir Dis.1978;118(1):119-133.

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024